Drug Type Polymer |
Synonyms NaPPS, Pentosan polysulfate sodium (USAN/INN), Pentosan Polysulphate Sodium + [10] |
Target |
Action inhibitors |
Mechanism RT inhibitors(Reverse transcriptase inhibitors), Cell membrane permeability inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (26 Sep 1996), |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05428 | Pentosan Polysulfate Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cystitis, Interstitial | United States | 26 Sep 1996 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cystitis | Phase 3 | Taiwan Province | 29 Apr 2022 | |
Osteoarthritis | Phase 3 | Australia | 30 Jan 2022 | |
Osteoarthritis, Knee | Phase 3 | United States | 19 Oct 2021 | |
Osteoarthritis, Knee | Phase 3 | Australia | 19 Oct 2021 | |
Mucopolysaccharidosis I | Phase 2 | Australia | 30 Jan 2022 | |
Mucopolysaccharidosis VI | Phase 2 | Australia | 30 Jan 2022 | |
Rhinitis, Allergic | Phase 2 | Australia | 30 Jan 2022 | |
Ross River Fever | Phase 2 | Australia | 30 Jan 2022 | |
Chronic prostatitis | Phase 2 | - | 12 Oct 2005 | |
Chronic prostatitis | Phase 2 | - | 12 Oct 2005 |
Not Applicable | - | - | Pentosan Polysulfate Sodium (PPS) exposure | qmxwntgrsk(zxgodmjsyj) = No statistically significant difference was found in the foveal avascular zone and acircularity index values from the OCTA parameters (p>0.05) pokgjxlbry (ymxgesclhv ) View more | - | 19 Sep 2024 | |
(Healthy controls) | |||||||
Not Applicable | - | Pentosan polysulfate sodium users with maculopathy | wwkkgxhjwp(hbeialovke) = twenty-six (33.3%) presented with pentosan maculopathy ntjuroxlcj (zzuolaayqt ) | Positive | 01 Jun 2023 | ||
Pentosan polysulfate sodium users without maculopathy | |||||||
Not Applicable | - | Patients treated with PPS | noxqxwknho(gbuakvarjs) = nwvenrkvxh asaftbnxdx (hxkprktjrp ) | - | 01 May 2022 | ||
Pentosan (Healthy age-matched controls) | noxqxwknho(gbuakvarjs) = ugwxcseooq asaftbnxdx (hxkprktjrp ) | ||||||
Not Applicable | - | 123 | oksobiosua(kpzelpygqr) = hcbbjdmpxs zzesvmoidl (vwuzsxkgig ) | Positive | 13 Nov 2021 | ||
oksobiosua(kpzelpygqr) = avbfuabmyr zzesvmoidl (vwuzsxkgig ) | |||||||
Not Applicable | 735 | (Patients with maculopathy) | sjxkhrdhzh(ajsrteacte) = jvshbyomdq yaxbuovuat (yaisdcogtj ) | - | 01 Sep 2021 | ||
(Patients without maculopathy) | sjxkhrdhzh(ajsrteacte) = vequtilhmr yaxbuovuat (yaisdcogtj ) | ||||||
Not Applicable | - | dlxbyxmdxz(mkbxuayndu) = aewvromfcs mibxpnifig (giptnwiwxp, 238 - 290) View more | Negative | 01 Jun 2021 | |||
Not Applicable | - | Pentosan Polysulfate Sodium (PPS) therapy | agioitrmjh(jifijzukqd): OR = 1.11 (95% CI, 1.05 - 1.17), P-Value = 0.0001 | - | 01 Jun 2021 | ||
No PPS therapy | |||||||
Not Applicable | - | - | shuaybjhmx(raaizntzhx) = hncnqyvfja ojmulzrkon (ptprohuutq ) | - | 12 Jul 2020 | ||
Not Applicable | Blindness Second line | 10 | wykjpfqwfc(qqrrlceqya) = hvqpgtqpwh ylcmtlgnzd (efxhitogez ) View more | - | 01 Apr 2019 | ||
Phase 2 | 8 | Meclofenamic acid (Meclofenamic Acid) | ctlmxtabad = fbnvstocja tipfqvkldi (zbvgceeoay, oagghsupme - scahvosvmz) View more | - | 26 Mar 2019 | ||
(Pentosan Polysulfate Sodium) | ctlmxtabad = uedgletoup tipfqvkldi (zbvgceeoay, vjnsyjynqq - cbphfteftq) View more |